Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Breast Cancer

  Free Subscription


04.09.2017

1 AJR Am J Roentgenol
1 Ann Surg Oncol
2 Anticancer Res
4 BMC Cancer
5 Br J Cancer
2 Breast Cancer
1 Breast Cancer (Dove Med Press)
1 Breast Cancer Res
8 Breast Cancer Res Treat
3 Breast J
3 Cancer Lett
1 Cancer Res
1 Clin Breast Cancer
3 Eur J Cancer
1 Exp Cell Res
2 Int J Cancer
1 Int J Radiat Oncol Biol Phys
2 J Clin Oncol
2 J Natl Cancer Inst
1 J Nucl Med
2 Nat Rev Clin Oncol
1 NPJ Breast Cancer
1 Oncogene
3 Oncol Rep
2 Oncology
3 PLoS One
1 Radiother Oncol


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    AJR Am J Roentgenol

  1. STRIGEL RM, Burnside ES, Elezaby M, Fowler AM, et al
    Utility of BI-RADS Assessment Category 4 Subdivisions for Screening Breast MRI.
    AJR Am J Roentgenol. 2017;208:1392-1399.
    PubMed     Text format     Abstract available


    Ann Surg Oncol

  2. SONG Z, Ye T, Ma L, Xiang J, et al
    Surgical Outcomes of Isolated Malignant Pulmonary Nodules in Patients with a History of Breast Cancer.
    Ann Surg Oncol. 2017 Aug 28. doi: 10.1245/s10434-017-6067.
    PubMed     Text format     Abstract available


    Anticancer Res

  3. MARIAMPILLAI AI, Cruz JPD, Suh J, Sivapiragasam A, et al
    Cancer Antigen 72-4 for the Monitoring of Advanced Tumors of the Gastrointestinal Tract, Lung, Breast and Ovaries.
    Anticancer Res. 2017;37:3649-3656.
    PubMed     Text format     Abstract available

  4. MADEKIVI V, Bostrom P, Aaltonen R, Vahlberg T, et al
    The Sentinel Node with Isolated Breast Tumor Cells or Micrometastases. Benefits and Risks of Axillary Dissection.
    Anticancer Res. 2017;37:3757-3762.
    PubMed     Text format     Abstract available


    BMC Cancer

  5. KASHIWAGI S, Fukushima W, Asano Y, Goto W, et al
    Identification of predictive markers of the therapeutic effect of eribulin chemotherapy for locally advanced or metastatic breast cancer.
    BMC Cancer. 2017;17:604.
    PubMed     Text format     Abstract available

  6. OBERGUGGENBERGER A, Martini C, Huber N, Fallowfield L, et al
    Self-reported sexual health: Breast cancer survivors compared to women from the general population - an observational study.
    BMC Cancer. 2017;17:599.
    PubMed     Text format     Abstract available

  7. LIMA MTM, de Carvalho KP, Mazzutti FS, de Almeida Maia M, et al
    Temporal influence of endocrine therapy with tamoxifen and chemotherapy on nutritional risk and obesity in breast cancer patients.
    BMC Cancer. 2017;17:578.
    PubMed     Text format    

  8. YAMASHITA Y, Nishiumi S, Kono S, Takao S, et al
    Differences in elongation of very long chain fatty acids and fatty acid metabolism between triple-negative and hormone receptor-positive breast cancer.
    BMC Cancer. 2017;17:589.
    PubMed     Text format     Abstract available


    Br J Cancer

  9. GURVITS N, Loyttyniemi E, Nykanen M, Kuopio T, et al
    Separase is a marker for prognosis and mitotic activity in breast cancer.
    Br J Cancer. 2017 Aug 31. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available

  10. PEDERSEN AB, Horvath-Puho E, Ehrenstein V, Rorth M, et al
    Frozen shoulder and risk of cancer: a population-based cohort study.
    Br J Cancer. 2017;117:144-147.
    PubMed     Text format     Abstract available

  11. SAMARENDRA H, Jones K, Petrinic T, Silva MA, et al
    A meta-analysis of CXCL12 expression for cancer prognosis.
    Br J Cancer. 2017;117:124-135.
    PubMed     Text format     Abstract available

  12. WEISS GJ, Waypa J, Blaydorn L, Coats J, et al
    A phase Ib study of pembrolizumab plus chemotherapy in patients with advanced cancer (PembroPlus).
    Br J Cancer. 2017;117:33-40.
    PubMed     Text format     Abstract available

  13. CAPELAN M, Battisti NML, McLoughlin A, Maidens V, et al
    The prevalence of unmet needs in 625 women living beyond a diagnosis of early breast cancer.
    Br J Cancer. 2017 Aug 31. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


    Breast Cancer

  14. HATTORI M, Ishiguro H, Masuda N, Yoshimura A, et al
    Phase I dose-finding study of eribulin and capecitabine for metastatic breast cancer: JBCRG-18 cape study.
    Breast Cancer. 2017 Aug 31. doi: 10.1007/s12282-017-0798.
    PubMed     Text format     Abstract available

  15. YAMAGUCHI T, Mukai H, Akiyama F, Arihiro K, et al
    Inter-observer agreement among pathologists in grading the pathological response to neoadjuvant chemotherapy in breast cancer.
    Breast Cancer. 2017 Aug 30. doi: 10.1007/s12282-017-0799.
    PubMed     Text format     Abstract available


    Breast Cancer (Dove Med Press)

  16. HOWELL SJ, Hockenhull K, Salih Z, Evans DG, et al
    Increased risk of breast cancer in neurofibromatosis type 1: current insights.
    Breast Cancer (Dove Med Press). 2017;9:531-536.
    PubMed     Text format     Abstract available


    Breast Cancer Res

  17. YUAN Y, Vora N, Sun CL, Li D, et al
    Association of pre-chemotherapy peripheral blood pro-inflammatory and coagulation factors with reduced relative dose intensity in women with breast cancer.
    Breast Cancer Res. 2017;19:101.
    PubMed     Text format     Abstract available


    Breast Cancer Res Treat

  18. ARCIERO CA, Yang J, Peng L, Ward KC, et al
    African American patients with breast cancer have worse prognosis than white patients in certain subtypes and stages.
    Breast Cancer Res Treat. 2017 Aug 30. doi: 10.1007/s10549-017-4484.
    PubMed     Text format     Abstract available

  19. HEITZ AE, Baumgartner RN, Baumgartner KB, Boone SD, et al
    Healthy lifestyle impact on breast cancer-specific and all-cause mortality.
    Breast Cancer Res Treat. 2017 Aug 31. doi: 10.1007/s10549-017-4467.
    PubMed     Text format     Abstract available

  20. VERHEUVEL NC, Voogd AC, Tjan-Heijnen VCG, Siesling S, et al
    Non-visualized sentinel nodes in breast cancer patients; prevalence, risk factors, and prognosis.
    Breast Cancer Res Treat. 2017 Aug 31. doi: 10.1007/s10549-017-4483.
    PubMed     Text format     Abstract available

  21. SUZUKI Y, Tsunoda H, Kimura T, Yamauchi H, et al
    BMI change and abdominal circumference are risk factors for breast cancer, even in Asian women.
    Breast Cancer Res Treat. 2017 Aug 31. doi: 10.1007/s10549-017-4481.
    PubMed     Text format     Abstract available

  22. HAMOOD R, Hamood H, Merhasin I, Keinan-Boker L, et al
    Chronic pain and other symptoms among breast cancer survivors: prevalence, predictors, and effects on quality of life.
    Breast Cancer Res Treat. 2017 Aug 31. doi: 10.1007/s10549-017-4485.
    PubMed     Text format     Abstract available

  23. AHMED M, Jozsa F, Baker R, Rubio IT, et al
    Erratum to: Meta-analysis of tumour burden in pre-operative axillary ultrasound positive and negative breast cancer patients.
    Breast Cancer Res Treat. 2017 Aug 30. doi: 10.1007/s10549-017-4457.
    PubMed     Text format    

  24. MALINIAK ML, Patel AV, McCullough ML, Campbell PT, et al
    Obesity, physical activity, and breast cancer survival among older breast cancer survivors in the Cancer Prevention Study-II Nutrition Cohort.
    Breast Cancer Res Treat. 2017 Aug 31. doi: 10.1007/s10549-017-4470.
    PubMed     Text format     Abstract available

  25. WATANABE J, Hayashi T, Tadokoro Y, Nishimura S, et al
    Clinical pattern of primary systemic therapy and outcomes of estrogen receptor-positive, HER2-negative metastatic breast cancer: a review of a single institution.
    Breast Cancer Res Treat. 2017 Aug 29. doi: 10.1007/s10549-017-4478.
    PubMed     Text format     Abstract available


    Breast J

  26. PALESH O, Scheiber C, Kesler S, Mustian K, et al
    Management of side effects during and post-treatment in breast cancer survivors.
    Breast J. 2017 Aug 27. doi: 10.1111/tbj.12862.
    PubMed     Text format     Abstract available

  27. MATHEW A, Achkar T, Abberbock S, Sandhu GS, et al
    Prevalence and determinants of end-of-life chemotherapy use in patients with metastatic breast cancer.
    Breast J. 2017 Aug 28. doi: 10.1111/tbj.12905.
    PubMed     Text format     Abstract available

  28. RODRIGUEZ CA, Martin T, Lozano R, Gomez A, et al
    Spontaneous nasal perforation in a bevacizumab-treated patient with metastatic breast cancer.
    Breast J. 2017 Aug 27. doi: 10.1111/tbj.12913.
    PubMed     Text format     Abstract available


    Cancer Lett

  29. WANG B, Zhao H, Zhao L, Zhang Y, et al
    Up-regulation of OLR1 expression by TBC1D3 through activation of TNFalpha/NF-kappaB pathway promotes the migration of human breast cancer cells.
    Cancer Lett. 2017 Aug 24. pii: S0304-3835(17)30508.
    PubMed     Text format     Abstract available

  30. QIN H, Liu X, Li F, Miao L, et al
    PAD1 promotes epithelial-mesenchymal transition and metastasis in triple-negative breast cancer cells by regulating MEK1-ERK1/2-MMP2 signaling.
    Cancer Lett. 2017 Aug 24. pii: S0304-3835(17)30506.
    PubMed     Text format     Abstract available

  31. FALLATAH M, Liu S, Sevigny MB, Zou H, et al
    Novel flexible heteroarotinoid, SL-1-18, promotes ERalpha degradation to inhibit breast cancer cell growth.
    Cancer Lett. 2017 Aug 24. pii: S0304-3835(17)30513.
    PubMed     Text format     Abstract available


    Cancer Res

  32. ROSS MH, Esser AK, Fox GC, Schmieder AH, et al
    Bone-induced expression of integrin beta3 enables targeted nanotherapy of breast cancer metastases.
    Cancer Res. 2017 Aug 30. pii: canres.1225.2017.
    PubMed     Text format     Abstract available


    Clin Breast Cancer

  33. NAMURA M, Tsunoda H, Yagata H, Hayashi N, et al
    Discrepancies Between Pathological Tumor Responses and Estimations of Complete Response by Magnetic Resonance Imaging After Neoadjuvant Chemotherapy Differ by Breast Cancer Subtype.
    Clin Breast Cancer. 2017 Jul 21. pii: S1526-8209(17)30107.
    PubMed     Text format     Abstract available


    Eur J Cancer

  34. FREDHOLM H, Magnusson K, Lindstrom LS, Tobin NP, et al
    Breast cancer in young women and prognosis: How important are proliferation markers?
    Eur J Cancer. 2017;84:278-289.
    PubMed     Text format     Abstract available

  35. SCHREUDER K, Kuijer A, Rutgers EJT, Smorenburg CH, et al
    Impact of gene-expression profiling in patients with early breast cancer when applied outside the guideline directed indication area.
    Eur J Cancer. 2017;84:270-277.
    PubMed     Text format     Abstract available

  36. ONEGA T, Weaver DL, Frederick PD, Allison KH, et al
    The diagnostic challenge of low-grade ductal carcinoma in situ.
    Eur J Cancer. 2017;80:39-47.
    PubMed     Text format     Abstract available


    Exp Cell Res

  37. HOU MF, Luo CW, Chang TM, Hung WC, et al
    The NuRD complex-mediated p21 suppression facilitates chemoresistance in BRCA-proficient breast cancer.
    Exp Cell Res. 2017 Aug 24. pii: S0014-4827(17)30450.
    PubMed     Text format     Abstract available


    Int J Cancer

  38. WU AH, Vigen C, Butler LM, Tseng CC, et al
    Metabolic conditions and breast cancer risk among Los Angeles County Filipina Americans compared with Chinese and Japanese Americans.
    Int J Cancer. 2017 Aug 26. doi: 10.1002/ijc.31018.
    PubMed     Text format     Abstract available

  39. BERTRAND KA, Gerlovin H, Bethea TN, Palmer JR, et al
    Pubertal growth and adult height in relation to breast cancer risk in African American women.
    Int J Cancer. 2017 Aug 28. doi: 10.1002/ijc.31019.
    PubMed     Text format     Abstract available


    Int J Radiat Oncol Biol Phys

  40. WOODWARD WA, Fang P, Arriaga L, Gao H, et al
    A Phase II Study of Preoperative Capecitabine and Concomitant Radiation in Women With Advanced Breast Cancer.
    Int J Radiat Oncol Biol Phys. 2017 May 3. pii: S0360-3016(17)30851.
    PubMed     Text format     Abstract available


    J Clin Oncol

  41. TEEPEN JC, van Leeuwen FE, Tissing WJ, van Dulmen-den Broeder E, et al
    Long-Term Risk of Subsequent Malignant Neoplasms After Treatment of Childhood Cancer in the DCOG LATER Study Cohort: Role of Chemotherapy.
    J Clin Oncol. 2017;35:2288-2298.
    PubMed     Text format     Abstract available

  42. GOETZ MP, Suman VJ, Reid JM, Northfelt DW, et al
    First-in-Human Phase I Study of the Tamoxifen Metabolite Z-Endoxifen in Women With Endocrine-Refractory Metastatic Breast Cancer.
    J Clin Oncol. 2017 Aug 30:JCO2017733246. doi: 10.1200/JCO.2017.73.3246.
    PubMed     Text format     Abstract available


    J Natl Cancer Inst

  43. TROESTER MA, Sun X, Allott EH, Geradts J, et al
    Racial Differences in PAM50 Subtypes in the Carolina Breast Cancer Study.
    J Natl Cancer Inst. 2018;110.
    PubMed     Text format     Abstract available

  44. HEINDL A, Sestak I, Naidoo K, Cuzick J, et al
    Relevance of Spatial Heterogeneity of Immune Infiltration for Predicting Risk of Recurrence After Endocrine Therapy of ER+ Breast Cancer.
    J Natl Cancer Inst. 2018;110.
    PubMed     Text format     Abstract available


    J Nucl Med

  45. HENRY KE, Dilling TR, Abdel-Atti D, Edwards KJ, et al
    Non-invasive 89Zr-Transferrin PET Shows Improved Tumor Targeting Compared to 18F-FDG PET in MYC-overexpressing Human Triple Negative Breast Cancer.
    J Nucl Med. 2017 Aug 28. pii: jnumed.117.192286. doi: 10.2967/jnumed.117.192286.
    PubMed     Text format     Abstract available


    Nat Rev Clin Oncol

  46. SIDAWAY P
    Breast Cancer: Evolution of metastatic disease revealed.
    Nat Rev Clin Oncol. 2017 Aug 31. doi: 10.1038/nrclinonc.2017.
    PubMed     Text format    

  47. SIDAWAY P
    Breast cancer: AKT inhibition effective against TNBC.
    Nat Rev Clin Oncol. 2017 Aug 31. doi: 10.1038/nrclinonc.2017.
    PubMed     Text format    


    NPJ Breast Cancer

  48. LIU D, Ho MF, Schaid DJ, Scherer SE, et al
    Breast cancer chemoprevention pharmacogenomics: Deep sequencing and functional genomics of the ZNF423 and CTSO genes.
    NPJ Breast Cancer. 2017;3:30.
    PubMed     Text format     Abstract available


    Oncogene

  49. KIM ES, Kim SY, Koh M, Lee HM, et al
    C-reactive protein binds to integrin alpha2 and Fcgamma receptor I, leading to breast cell adhesion and breast cancer progression.
    Oncogene. 2017 Aug 28. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


    Oncol Rep

  50. OH YJ, Seo YH
    A novel chalcone-based molecule, BDP inhibits MDAMB231 triple-negative breast cancer cell growth by suppressing Hsp90 function.
    Oncol Rep. 2017 Aug 25. doi: 10.3892/or.2017.5925.
    PubMed     Text format     Abstract available

  51. LI Y, Zhou W, Tang K, Chen X, et al
    Silencing Aurora A leads to re-sensitization of breast cancer cells to Taxol through downregulation of SRC-mediated ERK and mTOR pathways.
    Oncol Rep. 2017 Aug 14. doi: 10.3892/or.2017.5908.
    PubMed     Text format     Abstract available

  52. GUO J, Gong G, Zhang B
    Screening and identification of potential biomarkers in triple-negative breast cancer by integrated analysis.
    Oncol Rep. 2017 Aug 21. doi: 10.3892/or.2017.5911.
    PubMed     Text format     Abstract available


    Oncology

  53. MUKAI H, Hagiwara Y, Imi K, Isaka H, et al
    The Impact of Treatment Preferences in Second-Line Chemotherapy on the Prognosis of HER2-Negative Metastatic Breast Cancer.
    Oncology. 2017 Aug 24. doi: 10.1159/000479033.
    PubMed     Text format     Abstract available

  54. AARTS MJ, Vriens BE, de Boer M, Peters FP, et al
    Neutrophil Recovery in Breast Cancer Patients Receiving Docetaxel-Containing Chemotherapy with and without Granulocyte Colony-Stimulating Factor Prophylaxis.
    Oncology. 2017 Aug 22. doi: 10.1159/000479067.
    PubMed     Text format     Abstract available


    PLoS One

  55. BOSL A, Spitzmuller A, Jasarevic Z, Rauch S, et al
    MammaPrint versus EndoPredict: Poor correlation in disease recurrence risk classification of hormone receptor positive breast cancer.
    PLoS One. 2017;12:e0183458.
    PubMed     Text format     Abstract available

  56. HANNA M, Dumas I, Orain M, Jacob S, et al
    Association between local inflammation and breast tissue age-related lobular involution among premenopausal and postmenopausal breast cancer patients.
    PLoS One. 2017;12:e0183579.
    PubMed     Text format     Abstract available

  57. MAHMOUD AM, Macias V, Al-Alem U, Deaton RJ, et al
    BRCA1 protein expression and subcellular localization in primary breast cancer: Automated digital microscopy analysis of tissue microarrays.
    PLoS One. 2017;12:e0184385.
    PubMed     Text format     Abstract available


    Radiother Oncol

  58. BROUWERS PJAM, van Loon J, Houben RMA, Paulissen J, et al
    Are PROMs sufficient to record late outcome of breast cancer patients treated with radiotherapy? A comparison between patient and clinician reported outcome through an outpatient clinic after 10years of follow up.
    Radiother Oncol. 2017 Aug 24. pii: S0167-8140(17)32511.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: